SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Summary - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

  • By

  • Andrea Surnit

  • June 9, 2026

  • 5 min

Share

Objective:

To investigate the association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and the incidence of kidney cancer in patients with type 2 diabetes, highlighting its significance in diabetes management.

Key Findings:
  • SGLT2 inhibitor users had 38 kidney cancer events (incidence rate of 18.9 per 100,000 person-years) compared to 64 events in DPP-4 users (30.8 per 100,000 person-years), totaling 102 events.
  • SGLT2 inhibitor use was associated with a 40% lower hazard of kidney cancer (hazard ratio 0.60, 95% CI 0.40 to 0.89).
  • The association remained consistent across various subgroups and sensitivity analyses.
Interpretation:

The findings suggest a potential association between SGLT2 inhibitor use and lower kidney cancer risk, with implications for clinical practice, but further validation is needed.

Limitations:
  • Observational design may introduce residual confounding.
  • Short follow-up period may not capture all kidney cancer cases.
  • Lack of tumor pathology data prevents subtype analysis.
  • Generalizability may be limited to Korean patients.
Conclusion:

The study indicates a lower incidence of kidney cancer among SGLT2 inhibitor users compared to DPP-4 inhibitor users, warranting further research to confirm these findings.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

Virtual Staining in the Tumor Microenvironment

AI models are generating virtual biomarker staining from hematoxylin and eosin slides at a fraction of the cost and time of the manual technique

  • April 23, 2026

  • 4 min